Results 41 to 50 of about 21,198 (196)

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

Lost and found in translation: the value of the human imiquimod model

British Journal of Clinical Pharmacology, EarlyView.
Topical imiquimod (IMQ), a Toll‐like receptor (TLR) 7 agonist, induces transient cutaneous inflammation and is widely used in preclinical research as a ‘psoriasis‐like’ mouse model. However, accumulating evidence indicates substantial divergence between IMQ‐driven biology and human plaque psoriasis pathogenesis.
Anouk C. Meijs, Juliette A. van den Noort, Salma Assil, Naomi B. Klarenbeek, Matthijs Moerland, Tessa Niemeyer‐van der Kolk, Robert Rissmann   +6 more
wiley   +1 more source

Imiquimod in dermatology: an overview [PDF]

, 2016
Imiquimod is an immune response modifier commercially available as a 3.75 and 5% cream. Topical imiquimod stimulates the innate and adaptive immune responses and induces cytokine production.
Edith Hanna, Abbas, Ossama M., Ossama Abbas, Abadi, Rami, Hanna, Edith, Rami Abadi   +5 more
core   +1 more source

Transfersomes with core and surface‐loaded NF‐κB p65 siRNA for enhanced transdermal transfection and effective treatment of psoriasis

BMEMat, EarlyView.
TCPL, a transfersome with Tween 80 and PEI, enables efficient transdermal siNF‐κB delivery, resolving PEI's toxicity issue. It promotes lysosomal escape and effective transfection, silences NF‐κB, modulates immunity, and inhibits angiogenesis, alleviating psoriasis. With good biocompatibility, TCPL holds strong clinical translation potential. Schematic
Hui Xing, Yuhui Yang, Ziyi Zhao, Kai Lv, Yiran Shao, Zhi Zhang, Dong Ma   +6 more
wiley   +1 more source

Confocal Microscopy and Lentigo Maligna: An in vivo Pilot Study for the Assessment of Response to Imiquimod Therapy. [PDF]

, 2019
BACKGROUND Reflectance confocal microscopy (RCM) is a noninvasive technique that provides real-time in vivo images of the epidermal layer. Imiquimod has been recommended as an alternative treatment in lentigo maligna (LM) when surgical excision is not
Hunger, Robert, Brand, Flurin L, Jafari, Morteza   +2 more
core   +2 more sources

Evaluating the Effects of Imiquimod on Paths of TLRs and Inflammatory Cytokines Signaling in Infected Macrophages with Leishmania major in Vitro and in Vivo

Iranian Journal of Parasitology
Background: Leishmania major is an obligate and intracellular pathogen and the macrophages are the cell hosts for L. major. Imiquimod stimulates macrophages to secrete different cytokines via the expression of TLRs.
Parisa Ebrahimisadr, Fatemeh Ghaffarifar, Javad Jabari, John Horton, Zohreh Sharifi, Abdolhossein Dalimi, Mohammad Saaid Dayer   +6 more
doaj   +1 more source

Imiquimod

, 2007
Imiquimod is an immune response-modifying agent that demonstrates potent antiviral and antitumour activity. Although it's use has been approved by the FDA (Food and Drug Administration) in the treatment of external genital and perianal warts, actinic ...
Ertam I., Unal I.
core   +1 more source

Imiquimod Reverses Chronic Toxoplasmosis-Associated Behavioral and Neurocognitive Anomalies in a Rat Model

Biomedicines
Toxoplasma gondii is the etiologic agent of toxoplasmosis, a highly prevalent parasitosis. Toxoplasma gondii (T. gondii) transits in the brain from acute (AT) to chronic toxoplasmosis (CT), under host immune control.
Shaymaa Itani, Maguy Hamie, Reem El Jammal, Wassim Abdine, Mark Doumit, Adib Charafeddine, Marwan El-Sabban, Cindy Patinote, Carine Masquefa, Pierre-Antoine Bonnet, Makram Obeid, Hiba El Hajj   +11 more
doaj   +1 more source

Vulvar vitiligo-like depigmentation and multiple halos of hypomelanosis at the trunk following treatment with imiquimod 5% cream for vulvar condylomata: casual or related events? [PDF]

Anais Brasileiros de Dermatologia, 2014
A 25-year-old Caucasian female with multiple genital warts involving the vulvar area was treated with imiquimod 5% cream. During follow-up the patient developed areas of hypopigmentation at the site of application of imiquimod cream and areas of ...
Maíra Chiarelli Serra, Claudia Menicanti, Elisabetta Pennacchioli, Giulio Tosti   +3 more
doaj   +1 more source

Dysregulation of Amino Acid Transporters in a Rat Model of TLR7-Mediated Maternal Immune Activation

Pharmaceutics, 2023
Maternal immune activation (MIA) during pregnancy is linked to neurodevelopmental disorders in humans. Similarly, the TLR7 agonist imiquimod alters neurodevelopment in rodents.
Eliza R. McColl, Jeffrey T. Henderson, Micheline Piquette-Miller   +2 more
doaj   +1 more source